Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 21;13(8):957.
doi: 10.3390/healthcare13080957.

Curative-Intention Surgery with Lobe-Specific Versus Systematic Lymph Node Dissection in Clinical Stage IA-IB Non-Small Cell Lung Cancer: Our Experience and Literature Review

Bogdan Cosmin Tanase  1 , Teodor Horvat  1 , Mihnea Davidescu  1 , Claudiu Eduard Nistor  2 , Calin Muntean  3 , Gabriel Veniamin Cozma  4   5 , Alin Nicola  6   7 , Felix Bratosin  8 , Sorina Maria Denisa Laitin  8 , Alin Burlacu  1
Affiliations

Curative-Intention Surgery with Lobe-Specific Versus Systematic Lymph Node Dissection in Clinical Stage IA-IB Non-Small Cell Lung Cancer: Our Experience and Literature Review

Bogdan Cosmin Tanase et al. Healthcare (Basel). .

Abstract

Background and objectives: The benefit of lobe-specific lymph node dissection (LS-LND) in non-small cell lung cancer (NSCLC) remains debated, especially in early-stage disease. Previous reviews often included all stages, leaving a gap in focused evaluations of clinical stage IA-IB NSCLC. This systematic review, supplemented by our institutional experience, aimed to compare overall survival (OS), recurrence-free survival (RFS), and postoperative complications between LS-LND and systematic lymph node dissection (S-LND) in clinical stage IA-IB NSCLC.

Methods: We retrospectively reviewed 24 patients treated at our institution (14 S-LND vs. 10 LS-LND). Data on patient demographics, operative details, OS, RFS, and postoperative complications were collected. Risk of bias was assessed using established methodological tools. A targeted literature search was conducted in PubMed, EMBASE, and Web of Science from inception to 14 April 2022. Only three articles (total n = 1101 patients) met inclusion criteria focusing on clinical stage IA-IB NSCLC who underwent curative-intent resection.

Results: LS-LND demonstrated comparable or slightly improved 5-year OS (range: 69.7-96.7%) versus S-LND (64.9-92.0%), and similar or slightly higher RFS (66.0-95.6% in LS-LND vs. 60.8-88.8% in S-LND). In our cohort, the 5-year OS was 78.6% in S-LND vs. 80.0% in LS-LND, and the 5-year RFS was 71.4% vs. 70.0%, respectively. Postoperative complications such as arrhythmias were less frequent in LS-LND groups overall. Our data showed a low rate of pneumonia in S-LND compared to LS-LND (7.1% vs. 10.0%); however, arrhythmias accounted for 14.3% in S-LND vs. 10.0% in LS-LND).

Conclusions: For clinical stage IA-IB NSCLC, LS-LND offers oncologic outcomes that are comparable to S-LND, with a potential for reduced postoperative complications. The findings from our institution align with these trends observed in the literature. While these results suggest potential advantages of lobe-specific approaches, definitive conclusions require further validation through larger, prospective randomized studies to confirm the clinical benefits of LS-LND in early-stage NSCLC.

Keywords: lung cancer; mediastinal lymph nodes; oncology; thoracic surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
Figure 2
Figure 2
Five-Year Overall Survival (OS). Hattori et al. (2021) [21], Zhao et al. (2021) [22], Ma et al. (2013) [23].
Figure 3
Figure 3
Five-Year Recurrence-Free Survival (RFS). Hattori et al. (2021) [21], Zhao et al. (2021) [22], Ma et al. (2013) [23].
See this image and copyright information in PMC

References

    1. Wang H.-Q., Zhao L., Zhao J., Wang Q. Analysis on early detection of Lung cancer by PET/CT scan. Asian Pac. J. Cancer Prev. 2015;16:2215–2217. doi: 10.7314/APJCP.2015.16.6.2215. - DOI - PubMed
    1. Torre M., Reda M., Musso V., Danuzzo F., Mohamed S., Conforti S. Diagnostic accuracy of endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) for mediastinal lymph node staging of lung cancer. Mediastinum. 2021;5:15. doi: 10.21037/med-21-2. - DOI - PMC - PubMed
    1. Goldstraw P., Chansky K., Crowley J., Rami-Porta R., Asamura H., Eberhardt W.E., Nicholson A.G., Groome P., Mitchell A., Bolejack V., et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J. Thorac. Oncol. 2016;11:39–51. doi: 10.1016/j.jtho.2015.09.009. - DOI - PubMed
    1. Wang Y., Darling G.E. Complete mediastinal lymph node dissection versus systematic lymph node sampling in surgical treatment of non-small cell lung cancer: Do we have the answer? J. Thorac. Dis. 2017;9:4169–4170. doi: 10.21037/jtd.2017.10.39. - DOI - PMC - PubMed
    1. Zhu X., Feng X., Huang Z., Xu W., Guo A., Xu J., Chen Z., Shen T., Zhou J., He Z. Analysis of related factors and treatment effect of chylothorax after lung surgery. J. Thorac. Dis. 2024;16:3291–3305. doi: 10.21037/jtd-24-692. - DOI - PMC - PubMed

LinkOut - more resources